



## EMCI Licenses OroSTIFF From University of Kansas

### MISSION, KANSAS - JULY 20, 2011

EMCI (Epic Medical Concepts & Innovations, Inc.) announced today that it has licensed new technology, the OroSTIFF, developed by Dr. Steven Barlow at the University of Kansas. The technology will have clinical application for children with cleft lip, and in patients with Parkinson's disease to assess the effectiveness of anti-parkinson medications. EMCI plans to commercialize the technology and sell the product worldwide.

"The OroSTIFF represents yet another breakthrough from KU for patients suffering from degenerative diseases," says Peter Lucas, COO of EMCI. "This technology will take much of the guesswork out of treatments."

CEO James Lucas says "As the state of Kansas continues to invest in biosciences, EMCI is poised to become one of the Midwest's leaders in medical device innovation. We are thrilled to once again be able to work with the University of Kansas and the Center for Technology Commercialization."

"We are pleased to continue working with EMCI in an effort to bring KU medical technologies to those who would benefit from them", says Jim Baxendale, Executive Director of the KU Center for Technology Commercialization.

### ABOUT EMCI

EMCI was founded by James Lucas and Peter Lucas. It has a focus on medical device innovation. The company has a solid history in

the medical device industry with more than 25 years of experience with medical devices.

Relatively unique in the industry, EMCI's work spans across several key areas:

- Large-scale production of devices it already has in the market
- Development of its own new technologies
- Development, commercialization and manufacturing of licensed technologies
- Productive partnerships with intellectual property owners
- World-class medical device outsourcing

The company has capabilities that start with engineering, prototyping and regulatory and go all the way through manufacturing, large-scale production, and after-sales service and repair. Current EMCI development projects include devices for neurological diagnosis and therapy, reconstructive surgery, and general thoracic surgery.

EMCI operates three facilities in the area including its new research and development lab at the Kansas Bioscience Authority's Venture Accelerator, and its corporate headquarters in Mission, KS.

To find out more about EMCI, please visit us on the web at [www.emci.co](http://www.emci.co).

Contact: Peter Lucas  
Chief Operating Officer  
Phone: 913-449-0720  
[plucas@emci.co](mailto:plucas@emci.co)